ALK and inflammatory myofibroblastic tumor: ALK1 IHC positivity, when seen, is pathognomonic of IMT and has prognostic and therapeutic implications, as it opens the door for targeted therapy with the tyrosine kinase inhibitor (TKI), crizotinib [1,8,14].